{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:24:22Z","timestamp":1793874262174,"version":"4.6.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"publisher","award":["BIO15\/CA\/022\/BC"],"award-info":[{"award-number":["BIO15\/CA\/022\/BC"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"publisher","award":["IT989-16"],"award-info":[{"award-number":["IT989-16"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.critrevonc.2021.103430","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T02:18:03Z","timestamp":1627611483000},"page":"103430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review"],"prefix":"10.1016","volume":"165","author":[{"given":"Maria","family":"Lopez-Santillan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elixabet","family":"Lopez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Alvarez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garazi","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-9321","authenticated-orcid":false,"given":"Javier","family":"Arzuaga-Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irune","family":"Ruiz-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Guerra-Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8679-6868","authenticated-orcid":false,"given":"Angela","family":"Gutierrez-Camino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idoia","family":"Martin-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6769","key":"10.1016\/j.critrevonc.2021.103430_bib0005","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"10091","key":"10.1016\/j.critrevonc.2021.103430_bib0010","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103430_bib0015","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1038\/s41467-018-06354-3","article-title":"Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma","volume":"9","author":"Arthur","year":"2018","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103430_bib0020","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.18632\/oncotarget.1877","article-title":"Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another \"double hit\" lymphoma with very poor outcome?","volume":"5","author":"Asmar","year":"2014","journal-title":"Oncotarget."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103430_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncb2008","article-title":"HERC2 coordinates ubiquitin-dependent assembly of DNA repair factors on damaged chromosomes","volume":"12","author":"Bekker-Jensen","year":"2010","journal-title":"Nat. Cell Biol."},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103430_bib0030","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/gcc.22072","article-title":"The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma","volume":"52","author":"Bertrand","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103430_bib0035","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3324\/haematol.2019.227892","article-title":"Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study","volume":"105","author":"Bolen","year":"2020","journal-title":"Haematologica."},{"key":"10.1016\/j.critrevonc.2021.103430_bib0040","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12885-016-2339-5","article-title":"Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer","volume":"16","author":"Bonanno","year":"2016","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103430_bib0045","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.3109\/10428194.2012.668286","article-title":"Role of nuclear factor-\u03baB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma","volume":"53","author":"Bu","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103430_bib0050","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3324\/haematol.2018.187583","article-title":"Aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics","volume":"103","author":"Campo","year":"2018","journal-title":"Haematologica"},{"issue":"50","key":"10.1016\/j.critrevonc.2021.103430_bib0055","doi-asserted-by":"crossref","first-page":"83294","DOI":"10.18632\/oncotarget.13065","article-title":"Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors","volume":"7","author":"Cao","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103430_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145037","article-title":"A20 mutation is not a prognostic marker for activated B-cell-like diffuse large B-cell lymphoma","volume":"10","author":"Cen","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103430_bib0065","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"issue":"1S2","key":"10.1016\/j.critrevonc.2021.103430_bib0070","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/sonc.2002.30153","article-title":"Rituximab in the treatment of diffuse large B-cell lymphomas","volume":"29","author":"Coiffier","year":"2002","journal-title":"Semin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103430_bib0075","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.critrevonc.2021.103430_bib0080","doi-asserted-by":"crossref","first-page":"16712","DOI":"10.18632\/oncotarget.3154","article-title":"Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?","volume":"6","author":"Dubois","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103430_bib0085","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1158\/1078-0432.CCR-15-2305","article-title":"Next-generation sequencing in diffuse large B-Cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study","volume":"22","author":"Dubois","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103430_bib0090","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-16-1922","article-title":"Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-Mutated diffuse large B-Cell lymphoma: analysis of 361 cases","volume":"23","author":"Dubois","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.critrevonc.2021.103430_bib0095","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1182\/blood-2016-11-747022","article-title":"Genetic profiling of","volume":"129","author":"Ennishi","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103430_bib0100","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1038\/leu.2014.184","article-title":"MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma","volume":"28","author":"Fern\u00e1ndez-Rodr\u00edguez","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103430_bib0105","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/sj.leu.2401901","article-title":"Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin\u2019s lymphoma","volume":"14","author":"Gr\u00f8nbaek","year":"2000","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.critrevonc.2021.103430_bib0110","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/sj.leu.2404856","article-title":"Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma","volume":"21","author":"Iqbal","year":"2007","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103430_bib0115","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103430_bib0120","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/1471-2407-8-266","article-title":"Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres","volume":"8","author":"Ji","year":"2008","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2021.103430_bib0125","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/leu.2016.135","article-title":"Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis","volume":"30","author":"Juskevicius","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103430_bib0130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-017-0438-7","article-title":"Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38\/07 prospective clinical trial cohort","volume":"10","author":"Juskevicius","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103430_bib0135","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/leu.2017.251","article-title":"Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets","volume":"32","author":"Karube","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103430_bib0140","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1080\/10428190410001713170","article-title":"Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature","volume":"45","author":"Kerbauy","year":"2004","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103430_bib0145","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11899-019-00518-8","article-title":"Front-line treatment of high grade B cell non-hodgkin lymphoma","volume":"14","author":"Kesavan","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"11","key":"10.1016\/j.critrevonc.2021.103430_bib0150","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nchembio.1084","article-title":"A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells","volume":"8","author":"Knutson","year":"2012","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103430_bib0155","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"20","key":"10.1016\/j.critrevonc.2021.103430_bib0160","doi-asserted-by":"crossref","first-page":"9798","DOI":"10.18632\/oncotarget.2394","article-title":"Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma","volume":"5","author":"Kristensen","year":"2014","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103430_bib0165","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/annonc\/mdf185","article-title":"p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas","volume":"13","author":"Leroy","year":"2002","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103430_bib0170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"issue":"9","key":"10.1016\/j.critrevonc.2021.103430_bib0175","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3109\/10428194.2010.502584","article-title":"PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma","volume":"51","author":"Liu","year":"2010","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"10.1016\/j.critrevonc.2021.103430_bib0180","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","article-title":"Genetic alterations and their clinical implications in DLBCL","volume":"16","author":"Miao","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103430_bib0185","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/sj.leu.2401761","article-title":"Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A","volume":"14","author":"M\u00f8ller","year":"2000","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.critrevonc.2021.103430_bib0190","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","article-title":"Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing","volume":"122","author":"Morin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2021.103430_bib0195","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1038\/bcj.2015.69","article-title":"Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma","volume":"5","author":"Novak","year":"2015","journal-title":"Blood Cancer J."},{"issue":"14","key":"10.1016\/j.critrevonc.2021.103430_bib0200","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"Project IN-HsLPF","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103430_bib0205","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1182\/blood.2019002699","article-title":"Distinct molecular profile of IRF4-rearranged large B-cell lymphoma","volume":"135","author":"Ramis-Zaldivar","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2021.103430_bib0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103430_bib0215","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103430_bib0220","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.beha.2018.07.014","article-title":"Management of relapsed\/refractory DLBCL","volume":"31","author":"Sarkozy","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"52","key":"10.1016\/j.critrevonc.2021.103430_bib0225","first-page":"e2388","article-title":"Impact of single or combined genomic alterations of TP53, MYC, and BCL2 on survival of patients with diffuse large B-Cell lymphomas: a retrospective cohort study","volume":"94","author":"Schiefer","year":"2015","journal-title":"Bull. Sch. Med. Md"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103430_bib0230","doi-asserted-by":"crossref","first-page":"35","DOI":"10.18632\/oncotarget.774","article-title":"SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients","volume":"4","author":"Schif","year":"2013","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.critrevonc.2021.103430_bib0235","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-Cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103430_bib0240","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/leu.2011.378","article-title":"BCL2 mutations in diffuse large B-cell lymphoma","volume":"26","author":"Schuetz","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103430_bib0245","first-page":"7","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.critrevonc.2021.103430_bib0250","first-page":"1413","article-title":"Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma","volume":"39","author":"Stefancikova","year":"2011","journal-title":"Int. J. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2021.103430_bib0255","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.critrevonc.2021.103430_bib0260","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/blood-2013-01-479865","article-title":"Analysis of FOXO1 mutations in diffuse large B-cell lymphoma","volume":"121","author":"Trinh","year":"2013","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.critrevonc.2021.103430_bib0265","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12920-019-0484-9","article-title":"Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma","volume":"12","author":"Voropaeva","year":"2019","journal-title":"BMC Med. Genomics"},{"issue":"5","key":"10.1016\/j.critrevonc.2021.103430_bib0270","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.blre.2018.03.005","article-title":"Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI","volume":"32","author":"Wight","year":"2018","journal-title":"Blood Rev."},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103430_bib0275","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103430_bib0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2021.103430_bib0285","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/leu.2016.243","article-title":"Loss of PRDM1\/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma","volume":"31","author":"Xia","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2021.103430_bib0290","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ebiom.2017.01.027","article-title":"B-cell function gene mutations in diffuse large B-cell lymphoma: a retrospective cohort study","volume":"16","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"issue":"19","key":"10.1016\/j.critrevonc.2021.103430_bib0295","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103430_bib0300","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.18632\/oncotarget.3479","article-title":"Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries","volume":"6","author":"Xu-Monette","year":"2015","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.critrevonc.2021.103430_bib0305","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1158\/1078-0432.CCR-15-2296","article-title":"Clinical and biologic significance of MYC genetic mutations in de novo diffuse large B-cell lymphoma","volume":"22","author":"Xu-Monette","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.critrevonc.2021.103430_bib0310","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2007-02-072082","article-title":"Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma","volume":"110","author":"Young","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2021.103430_bib0315","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2008-01-129783","article-title":"Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study","volume":"112","author":"Young","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2021.103430_bib0320","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.leukres.2008.06.022","article-title":"TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype","volume":"33","author":"Zainuddin","year":"2009","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2021.103430_bib0325","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.3892\/or.2017.5891","article-title":"Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas","volume":"38","author":"Zlamalikova","year":"2017","journal-title":"Oncol. Rep."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821002183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821002183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:37:18Z","timestamp":1760902638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821002183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":65,"alternative-id":["S1040842821002183"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103430","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103430"}}